In March 2011 NICE introduced guidelines that recommended the prescription of memantine for patients with moderate to severe Alzheimer’s disease or for those people who could not tolerate AChE inhibitors. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.